首页 > 最新文献

Prostate Cancer and Prostatic Diseases最新文献

英文 中文
Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality 罕见组织学前列腺癌亚型:癌症特异性死亡率和其他原因死亡率
IF 4.8 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-10 DOI: 10.1038/s41391-024-00866-4
Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A. Goyal, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Stefano Puliatti, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Benedikt Hoeh, Philipp Mandel, Luis A. Kluth, Felix K. H. Chun, Pierre I. Karakiewicz

Background

To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes.

Methods

Using the Surveillance, Epidemiology, and End Results database (2004–2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models.

Results

Of 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all p < 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients.

Conclusions

Compared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.

背景评估罕见组织学亚型前列腺癌患者的癌症特异性死亡率(CSM)和其他原因死亡率(OCM)。结果在 827,549 例患者中,1510 例(0.18%)患有导管癌,952 例(0.12%)患有神经内分泌癌,462 例(0.06%)患有粘液腺癌,95 例(0.01%)患有标志环细胞癌。在局部晚期阶段,5 年 CSM 与 OCM 的比率分别为:针状癌 2% 与 10%,粘液腺癌 3% 与 8%,神经内分泌癌 55% 与 19%。在局部晚期阶段,针状癌患者的五年CSM与OCM对比率为5%比6%,导管癌患者为14%比16%,神经内分泌癌患者为71%比15%。在转移阶段,标志环细胞和粘液腺癌的五年CSM与OCM比率分别为49%和16%,导管癌为63%和9%,神经内分泌癌为85%和12%。在多变量CRR中,局部神经内分泌癌(HR 3.09)、局部晚期神经内分泌癌(HR 9.66)、局部晚期导管癌(HR 2.26)和最终转移性神经内分泌癌患者(HR 3.57;均为P < 0.结论与尖腺癌相比,各期神经内分泌癌和局部晚期导管癌患者的 CSM 率更高。相反,粘液腺癌和印戒细胞腺癌的 CSM 率与尖腺癌没有差异。
{"title":"Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality","authors":"Carolin Siech, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Natali Rodriguez Peñaranda, Jordan A. Goyal, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Stefano Puliatti, Nicola Longo, Ottavio de Cobelli, Alberto Briganti, Benedikt Hoeh, Philipp Mandel, Luis A. Kluth, Felix K. H. Chun, Pierre I. Karakiewicz","doi":"10.1038/s41391-024-00866-4","DOIUrl":"https://doi.org/10.1038/s41391-024-00866-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Using the Surveillance, Epidemiology, and End Results database (2004–2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all <i>p</i> &lt; 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Compared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141571614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms. 开发并验证用于预测下尿路症状男性前列腺炎症的临床提名图。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-06 DOI: 10.1038/s41391-024-00857-5
Stavros Gravas, Cosimo De Nunzio, Luís Campos Pinheiro, Javier Ponce de León, Konstantinos Skriapas, Ziad Milad, Riccardo Lombardo, Mariana Medeiros, Pantelis Makrides, Michael Samarinas, Mauro Gacci

Background: Prostatic inflammation is an important etiological component of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The Prostatic Inflammation Nomogram Study (PINS) aimed to develop and validate a nomogram for predicting the presence of prostatic inflammation in men with LUTS.

Methods: This non-interventional, cross-sectional, prospective study was conducted in six secondary/tertiary centers across Cyprus, Greece, Italy, Portugal, and Spain. Men (≥40 years) with BPH/LUTS scheduled to undergo prostatic surgery or transrectal ultrasound-guided (TRUS) prostate biopsy were included. Fifteen demographic and clinical participant characteristics were selected as possible predictors of prostatic inflammation. The presence of inflammation (according to Irani score) in the prostatic tissue samples obtained from surgery/TRUS biopsy was determined. The effect of each characteristic on the likelihood a prostate specimen demonstrated inflammation (classified by Irani score into two categories, 0-2 [no/minimal inflammation] or 3-6 [moderate/severe inflammation]) was assessed using multiple logistic regression. A nomogram was developed and its discriminatory ability and validity were assessed.

Results: In total, 423 patients (mean age 68.9 years) were recruited. Prostate volume ultrasound (PVUS) > 50 mL, history of urinary tract infection (UTI) treatment, presence of diabetes, and International Prostate Symptom Score (IPPS) Storage score were statistically significant predictors of Irani classification. Logistic regression demonstrated a statistically significant effect for leucocytes detected via urine dipstick, presence of diabetes, PVUS > 50 mL, history of UTIs, and higher IPSS Storage score for the odds of an inflammatory score category of 3-6 versus 0-2. The nomogram had a concordance index of 0.71, and good internal validity.

Conclusions: The nomogram developed from PINS had good predictive ability and identified various characteristics to be predictors of prostatic inflammation. Use of the nomogram may aid in individualizing treatment for LUTS, by identifying individuals who are candidates for therapies targeting prostatic inflammation.

背景:前列腺炎症是良性前列腺增生症(BPH)和下尿路症状(LUTS)的重要病因。前列腺炎症提名图研究(PINS)旨在开发和验证一种提名图,用于预测患有下尿路症状的男性是否存在前列腺炎症:这项非干预性、横断面、前瞻性研究在塞浦路斯、希腊、意大利、葡萄牙和西班牙的六个二级/三级中心进行。研究对象包括计划接受前列腺手术或经直肠超声引导(TRUS)前列腺活检的良性前列腺增生症/前列腺痛(BPH/LUTS)男性患者(≥40 岁)。研究人员选择了 15 个人口统计学和临床参与者特征作为前列腺炎症的可能预测因素。确定了手术/TRUS 活检获得的前列腺组织样本中是否存在炎症(根据伊尼评分)。使用多重逻辑回归评估了每个特征对前列腺标本显示炎症(按伊尼评分分为 0-2 [无/轻度炎症] 或 3-6 [中度/重度炎症] 两类)的可能性的影响。结果:共招募了 423 名患者(平均年龄 68.9 岁)。前列腺体积超声(PVUS)> 50 mL、尿路感染(UTI)治疗史、糖尿病和国际前列腺症状评分(IPPS)存储评分对 Irani 分级有显著的统计学预测作用。逻辑回归结果表明,通过尿液浸量计检测到的白细胞、糖尿病、PVUS > 50 mL、UTI 治疗史和较高的 IPSS 存储评分对炎症评分类别为 3-6 和 0-2 的几率具有统计学意义。该提名图的一致性指数为 0.71,具有良好的内部有效性:根据 PINS 开发的提名图具有良好的预测能力,并确定了可预测前列腺炎症的各种特征。使用该提名图可以帮助对前列腺痛进行个体化治疗,确定哪些人适合采用针对前列腺炎症的疗法。
{"title":"Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms.","authors":"Stavros Gravas, Cosimo De Nunzio, Luís Campos Pinheiro, Javier Ponce de León, Konstantinos Skriapas, Ziad Milad, Riccardo Lombardo, Mariana Medeiros, Pantelis Makrides, Michael Samarinas, Mauro Gacci","doi":"10.1038/s41391-024-00857-5","DOIUrl":"https://doi.org/10.1038/s41391-024-00857-5","url":null,"abstract":"<p><strong>Background: </strong>Prostatic inflammation is an important etiological component of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The Prostatic Inflammation Nomogram Study (PINS) aimed to develop and validate a nomogram for predicting the presence of prostatic inflammation in men with LUTS.</p><p><strong>Methods: </strong>This non-interventional, cross-sectional, prospective study was conducted in six secondary/tertiary centers across Cyprus, Greece, Italy, Portugal, and Spain. Men (≥40 years) with BPH/LUTS scheduled to undergo prostatic surgery or transrectal ultrasound-guided (TRUS) prostate biopsy were included. Fifteen demographic and clinical participant characteristics were selected as possible predictors of prostatic inflammation. The presence of inflammation (according to Irani score) in the prostatic tissue samples obtained from surgery/TRUS biopsy was determined. The effect of each characteristic on the likelihood a prostate specimen demonstrated inflammation (classified by Irani score into two categories, 0-2 [no/minimal inflammation] or 3-6 [moderate/severe inflammation]) was assessed using multiple logistic regression. A nomogram was developed and its discriminatory ability and validity were assessed.</p><p><strong>Results: </strong>In total, 423 patients (mean age 68.9 years) were recruited. Prostate volume ultrasound (PVUS) > 50 mL, history of urinary tract infection (UTI) treatment, presence of diabetes, and International Prostate Symptom Score (IPPS) Storage score were statistically significant predictors of Irani classification. Logistic regression demonstrated a statistically significant effect for leucocytes detected via urine dipstick, presence of diabetes, PVUS > 50 mL, history of UTIs, and higher IPSS Storage score for the odds of an inflammatory score category of 3-6 versus 0-2. The nomogram had a concordance index of 0.71, and good internal validity.</p><p><strong>Conclusions: </strong>The nomogram developed from PINS had good predictive ability and identified various characteristics to be predictors of prostatic inflammation. Use of the nomogram may aid in individualizing treatment for LUTS, by identifying individuals who are candidates for therapies targeting prostatic inflammation.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing questions related to "incidence of prostate cancer in trans-women in the US: a large database analysis". 解决与 "美国变性女性的前列腺癌发病率:大型数据库分析 "相关的问题。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-05 DOI: 10.1038/s41391-024-00863-7
Matthew Loria, Tomasz Tabernacki, David Gilbert, Mart Andrew Maravillas, Megan McNamara, Shubham Gupta, Kirtishri Mishra
{"title":"Addressing questions related to \"incidence of prostate cancer in trans-women in the US: a large database analysis\".","authors":"Matthew Loria, Tomasz Tabernacki, David Gilbert, Mart Andrew Maravillas, Megan McNamara, Shubham Gupta, Kirtishri Mishra","doi":"10.1038/s41391-024-00863-7","DOIUrl":"https://doi.org/10.1038/s41391-024-00863-7","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. 在 Apa-RP 研究中,皮疹管理指南对接受阿帕鲁胺治疗高危局部前列腺癌患者的影响。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-07-05 DOI: 10.1038/s41391-024-00858-4
Neal Shore, Jason Hafron, Daniel Saltzstein, Amitabha Bhaumik, Pankaj Aggarwal, Jennifer Phillips, Tracy McGowan

Background/objectives: Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.

Subjects/methods: A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.

Results: Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.

Conclusions: Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.

背景/目的:根据SPARTAN和TITAN研究,阿帕鲁胺被批准用于治疗非转移性阉割耐药和转移性阉割敏感前列腺癌患者。皮疹是各适应症中常见的不良反应。我们假设早期识别和干预可以改善皮疹的治疗效果:向所有入组 Apa-RP (NCT04523207) 的患者提供了预设的皮疹管理指南,其中概述了推荐的皮肤护理方法。将 Apa-RP 中与皮疹相关的安全性数据与 SPARTAN 和 TITAN 的数据进行了描述性比较:结果:与 SPARTAN 和 TITAN 相比,Apa-RP 患者的皮疹相关结果有所改善:结论:提高警惕和积极管理可降低阿帕鲁胺治疗期间皮疹的发生率、严重程度和持续时间。
{"title":"Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.","authors":"Neal Shore, Jason Hafron, Daniel Saltzstein, Amitabha Bhaumik, Pankaj Aggarwal, Jennifer Phillips, Tracy McGowan","doi":"10.1038/s41391-024-00858-4","DOIUrl":"https://doi.org/10.1038/s41391-024-00858-4","url":null,"abstract":"<p><strong>Background/objectives: </strong>Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.</p><p><strong>Subjects/methods: </strong>A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.</p><p><strong>Results: </strong>Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.</p><p><strong>Conclusions: </strong>Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should systematic prostatic biopsies be discontinued? 是否应该停止系统性前列腺活检?
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-27 DOI: 10.1038/s41391-024-00849-5
Laurence Klotz

Introduction: The use of systematic biopsies in addition to targeted biopsies is based on multiple studies showing that 15-20% of "clinically significant" cancers are missed on targeted biopsies. Concern about these 'missed' cancers drives many interventions. This includes systematic biopsies in men with negative imaging and in men having targeted biopsies, and drives a preference for total gland treatment in men who may be candidates for partial gland ablation. This article summarizes recent genomic and clinical data indicating that, despite "clinically significant" histology, MRI invisible lesions are genomically and clinically favorable. These studies have demonstrated that the genetic aberrations associated with cancer visibility are the same aberrations that drive cancer invasiveness and metastasis. Thus invisible cancers, even if undiagnosed at baseline, are in most cases indolent and pose little threat to the patient. The implications are that patients should be monitored with imaging rather than systematic biopsy, and subject to repeat targeted biopsy for evidence of MR progression. Patients prefer this strategy. It has many advantages in terms of reduced burden of care, cost, psychological benefits, and less diagnosis of insignificant cancer.

Conclusion: It is now appropriate to abandon systematic biopsies in most patients.

介绍:多项研究表明,靶向活检会漏检 15-20% 具有 "临床意义 "的癌症,因此,除靶向活检外,还需使用系统活检。对这些 "漏检 "癌症的担忧推动了许多干预措施的实施。这包括对影像学检查阴性的男性和进行靶向活检的男性进行系统性活检,并倾向于对可能适合部分腺体消融的男性进行全腺体治疗。本文总结了最近的基因组学和临床数据,这些数据表明,尽管组织学上 "有临床意义",但核磁共振成像看不见的病灶在基因组学和临床上都是有利的。这些研究表明,与癌症可见性相关的基因畸变正是导致癌症侵袭和转移的畸变。因此,隐匿性癌症即使在基线时未被诊断出来,在大多数情况下也是不活跃的,对患者的威胁很小。其意义在于,应通过成像而非系统活检对患者进行监测,并在有 MR 进展的证据时重复进行有针对性的活检。患者更喜欢这种策略。它在减轻护理负担、成本、心理益处以及减少对不重要癌症的诊断等方面有很多优势:结论:现在对大多数患者放弃系统性活检是合适的。
{"title":"Should systematic prostatic biopsies be discontinued?","authors":"Laurence Klotz","doi":"10.1038/s41391-024-00849-5","DOIUrl":"https://doi.org/10.1038/s41391-024-00849-5","url":null,"abstract":"<p><strong>Introduction: </strong>The use of systematic biopsies in addition to targeted biopsies is based on multiple studies showing that 15-20% of \"clinically significant\" cancers are missed on targeted biopsies. Concern about these 'missed' cancers drives many interventions. This includes systematic biopsies in men with negative imaging and in men having targeted biopsies, and drives a preference for total gland treatment in men who may be candidates for partial gland ablation. This article summarizes recent genomic and clinical data indicating that, despite \"clinically significant\" histology, MRI invisible lesions are genomically and clinically favorable. These studies have demonstrated that the genetic aberrations associated with cancer visibility are the same aberrations that drive cancer invasiveness and metastasis. Thus invisible cancers, even if undiagnosed at baseline, are in most cases indolent and pose little threat to the patient. The implications are that patients should be monitored with imaging rather than systematic biopsy, and subject to repeat targeted biopsy for evidence of MR progression. Patients prefer this strategy. It has many advantages in terms of reduced burden of care, cost, psychological benefits, and less diagnosis of insignificant cancer.</p><p><strong>Conclusion: </strong>It is now appropriate to abandon systematic biopsies in most patients.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ChatGPT can help guide and empower patients after prostate cancer diagnosis. ChatGPT 可以在前列腺癌确诊后为患者提供指导和帮助。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-26 DOI: 10.1038/s41391-024-00864-6
Harry Collin, Kandice Keogh, Marnique Basto, Stacy Loeb, Matthew J Roberts

Background/objectives: Patients often face uncertainty about what they should know after prostate cancer diagnosis. Web-based information is common but is at risk of being of poor quality or readability.

Subjects/methods: We used ChatGPT, a freely available Artificial intelligence (AI) platform, to generate enquiries about prostate cancer that a newly diagnosed patient might ask and compared to Google search trends. Then, we evaluated ChatGPT responses to these questions for clinical appropriateness and quality using standardised tools.

Results: ChatGPT generates broad and representative questions, and provides understandable, clinically sound advice.

Conclusions: AI can guide and empower patients after prostate cancer diagnosis through education. However, the limitations of the ChatGPT language-model must not be ignored and require further evaluation and optimisation in the healthcare field.

背景/目的:患者在确诊前列腺癌后往往不清楚自己应该知道些什么。基于网络的信息很常见,但存在质量或可读性差的风险:我们使用免费提供的人工智能(AI)平台 ChatGPT 生成新确诊患者可能提出的有关前列腺癌的询问,并与谷歌搜索趋势进行比较。然后,我们使用标准化工具评估了 ChatGPT 对这些问题的回复的临床适宜性和质量:结果:ChatGPT 生成了广泛而有代表性的问题,并提供了易于理解、临床上合理的建议:结论:通过教育,人工智能可以在前列腺癌确诊后为患者提供指导并增强其能力。然而,ChatGPT 语言模型的局限性不容忽视,需要在医疗保健领域进一步评估和优化。
{"title":"ChatGPT can help guide and empower patients after prostate cancer diagnosis.","authors":"Harry Collin, Kandice Keogh, Marnique Basto, Stacy Loeb, Matthew J Roberts","doi":"10.1038/s41391-024-00864-6","DOIUrl":"https://doi.org/10.1038/s41391-024-00864-6","url":null,"abstract":"<p><strong>Background/objectives: </strong>Patients often face uncertainty about what they should know after prostate cancer diagnosis. Web-based information is common but is at risk of being of poor quality or readability.</p><p><strong>Subjects/methods: </strong>We used ChatGPT, a freely available Artificial intelligence (AI) platform, to generate enquiries about prostate cancer that a newly diagnosed patient might ask and compared to Google search trends. Then, we evaluated ChatGPT responses to these questions for clinical appropriateness and quality using standardised tools.</p><p><strong>Results: </strong>ChatGPT generates broad and representative questions, and provides understandable, clinically sound advice.</p><p><strong>Conclusions: </strong>AI can guide and empower patients after prostate cancer diagnosis through education. However, the limitations of the ChatGPT language-model must not be ignored and require further evaluation and optimisation in the healthcare field.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141458935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual outcomes in men who have sex with men who underwent radical prostatectomy. 接受根治性前列腺切除术的男男性行为者的性结果。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-25 DOI: 10.1038/s41391-024-00861-9
F Vedovo, C Lonati, N Suardi, L Mariani, P Capogrosso, V Ficarra, A Salonia, C Trombetta

Background: Sexual difficulties are a recognized consequence of prostate cancer (PCa) treatments. An estimated one in three men who have sex with men (MSM) receive PCa a diagnosis during their lifetime. MSM may experience all types of sexual dysfunction as reported in men who have sex with women (MSW), along with a number of more specific bothersome problems. This systematic literature review aims to evaluate sexual outcomes in MSM who have undergone radical prostatectomy (RP).

Methods: A systematic review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The searches were made using relevant keywords in the PubMed, Scopus, and Web of Science databases, thus including the whole literature from January 2000 to November 2023. Studies which did not allow to retrieve data on sexual outcomes on MSM treated with RP for PCa were excluded. Data on sexual outcomes and health-related quality of life (HRQoL) were retrieved, mostly including changes in libido, erectile function, ejaculatory disorders, orgasm, climacturia, changes in role-in-sex identity, changes in sexual partnerships, and the presence of painful receptive anal intercourses (AI).

Prospero id: CRD42024502592.

Results: Six articles met the inclusion criteria. In total, data of 260 patients were analyzed. Three main themes emerged: (a) MSM may experience specific sexual dysfunctions due to the different dynamics of their intimacy; (b) the lack of tool validated on gay and bisexual population to assess sexual outcomes (c) the need for a tailored approach that also takes into account sexual orientation throughout the oncological journey.

Conclusions: MSM undergoing RP may experience similar sexual problems as MSW. Painful AI should be considered a potential post-operative adverse outcome in MSM. Future studies should prioritize validating a questionnaire that explores AI. Healthcare providers should adopt a tailored approach that takes into account sexual orientation throughout the cancer journey.

背景:性生活困难是公认的前列腺癌(PCa)治疗的后果。据估计,每三名男男性行为者(MSM)中就有一名在其一生中被诊断出患有前列腺癌。男男性行为者可能会经历与女男性行为者(MSW)报告的所有类型的性功能障碍,以及一些更具体的困扰问题。本系统性文献综述旨在评估接受根治性前列腺切除术(RP)的 MSM 的性功能结果:方法:按照《系统综述和元分析首选报告项目》(PRISMA)指南进行了系统综述。在 PubMed、Scopus 和 Web of Science 数据库中使用相关关键词进行检索,从而将 2000 年 1 月至 2023 年 11 月期间的所有文献都包括在内。无法检索到接受 PCa RP 治疗的 MSM 的性结果数据的研究被排除在外。我们检索了有关性结果和健康相关生活质量(HRQoL)的数据,主要包括性欲变化、勃起功能、射精障碍、性高潮、排尿困难、性角色认同变化、性伴侣关系变化以及肛交疼痛(AI):CRD42024502592.Results:六篇文章符合纳入标准。共分析了 260 名患者的数据。结果:共有六篇文章符合纳入标准,共分析了 260 名患者的数据,得出三大主题:(a)由于亲密关系的动态不同,MSM 可能会出现特殊的性功能障碍;(b)缺乏针对男同性恋和双性恋人群的有效工具来评估性功能结果;(c)在整个肿瘤治疗过程中,需要一种考虑到性取向的定制方法:结论:接受 RP 治疗的 MSM 可能会遇到与 MSW 类似的性问题。在 MSM 中,AI 疼痛应被视为一种潜在的术后不良后果。未来的研究应优先验证探讨 AI 的问卷。医疗服务提供者应采取有针对性的方法,在整个癌症治疗过程中考虑到性取向问题。
{"title":"Sexual outcomes in men who have sex with men who underwent radical prostatectomy.","authors":"F Vedovo, C Lonati, N Suardi, L Mariani, P Capogrosso, V Ficarra, A Salonia, C Trombetta","doi":"10.1038/s41391-024-00861-9","DOIUrl":"https://doi.org/10.1038/s41391-024-00861-9","url":null,"abstract":"<p><strong>Background: </strong>Sexual difficulties are a recognized consequence of prostate cancer (PCa) treatments. An estimated one in three men who have sex with men (MSM) receive PCa a diagnosis during their lifetime. MSM may experience all types of sexual dysfunction as reported in men who have sex with women (MSW), along with a number of more specific bothersome problems. This systematic literature review aims to evaluate sexual outcomes in MSM who have undergone radical prostatectomy (RP).</p><p><strong>Methods: </strong>A systematic review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The searches were made using relevant keywords in the PubMed, Scopus, and Web of Science databases, thus including the whole literature from January 2000 to November 2023. Studies which did not allow to retrieve data on sexual outcomes on MSM treated with RP for PCa were excluded. Data on sexual outcomes and health-related quality of life (HRQoL) were retrieved, mostly including changes in libido, erectile function, ejaculatory disorders, orgasm, climacturia, changes in role-in-sex identity, changes in sexual partnerships, and the presence of painful receptive anal intercourses (AI).</p><p><strong>Prospero id: </strong>CRD42024502592.</p><p><strong>Results: </strong>Six articles met the inclusion criteria. In total, data of 260 patients were analyzed. Three main themes emerged: (a) MSM may experience specific sexual dysfunctions due to the different dynamics of their intimacy; (b) the lack of tool validated on gay and bisexual population to assess sexual outcomes (c) the need for a tailored approach that also takes into account sexual orientation throughout the oncological journey.</p><p><strong>Conclusions: </strong>MSM undergoing RP may experience similar sexual problems as MSW. Painful AI should be considered a potential post-operative adverse outcome in MSM. Future studies should prioritize validating a questionnaire that explores AI. Healthcare providers should adopt a tailored approach that takes into account sexual orientation throughout the cancer journey.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating risk calculators into routine clinical workflow for the detection of prostate cancer: next steps to achieve widespread adoption 将风险计算器纳入检测前列腺癌的常规临床工作流程:实现广泛采用的下一步措施。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-20 DOI: 10.1038/s41391-024-00859-3
Cody M. Anger, James L. Stallworth, Soroush Rais-Bahrami
{"title":"Integrating risk calculators into routine clinical workflow for the detection of prostate cancer: next steps to achieve widespread adoption","authors":"Cody M. Anger,&nbsp;James L. Stallworth,&nbsp;Soroush Rais-Bahrami","doi":"10.1038/s41391-024-00859-3","DOIUrl":"10.1038/s41391-024-00859-3","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41391-024-00859-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark” 更正:关于 "重新评估'自上而下'的 HoLEP:将前纤维肌基质作为手术标志的案例 "的编辑评论。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-20 DOI: 10.1038/s41391-024-00860-w
Hazem Elmansy
{"title":"Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”","authors":"Hazem Elmansy","doi":"10.1038/s41391-024-00860-w","DOIUrl":"10.1038/s41391-024-00860-w","url":null,"abstract":"","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41391-024-00860-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. 立体定向体放射治疗转移性耐阉割前列腺癌的现状。
IF 5.1 2区 医学 Q1 ONCOLOGY Pub Date : 2024-06-19 DOI: 10.1038/s41391-024-00862-8
Jennifer Le Guevelou, Francesco Cuccia, Ronan Flippot, Giuseppe Ferrera, Mario Terlizzi, Thomas Zilli, Renaud De Crevoisier, Jean-Michel Hannoun-Levi, Stephane Supiot, Paul Sargos, David Pasquier

Background: The onset of castration-resistance is associated with dismal outcomes in patients with prostate cancer (PCa). Metastasis directed therapy has been investigated in multiple disease settings and may improve outcomes in selected patients. Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC).

Methods: The literature search was performed on March 2024, on Pubmed, using the keywords "SBRT" AND "CRPC", and "stereotactic ablative radiotherapy (SABR)" AND "CRPC". This search retrieved a total of 108 articles, 19 were included.

Results: The literature is largely dominated by retrospective series. In men with metachronous oligoprogression, SBRT with androgen receptor pathway inhibitor significantly increased progression-free survival (PFS) including biochemical progression-free survival in a randomized phase II trial (hazard ratio of 0.35, p < 0.001). In patients continuing ADT, the bPFS ranged between 9.5 months to 17.9 months, and next systemic treatment-free survival (NEST-FS) reached up to 2 years. In men with induced oligoprogression, SBRT enabled NEST-FS up to 3 years. SBRT was well tolerated, with less than 5% grade 3 toxicity reported across studies.

Conclusion: In the population of patients with oligometastatic CRPC, SBRT enables long-term biochemical response and PFS. In the oligoprogressive setting, SBRT could be integrated to prolong the duration and efficacy of systemic therapies. Nevertheless, the level of evidence remains very low and inclusion within prospective trials remain the preferred option for this population of patients.

背景:阉割抗药性的出现与前列腺癌(PCa)患者的预后不佳有关。转移导向疗法已在多种疾病环境中进行了研究,可改善特定患者的预后。我们的系统性综述旨在总结立体定向体放射治疗(SBRT)治疗阉割抵抗性前列腺癌(CRPC)的证据:方法:我们于 2024 年 3 月在 Pubmed 上使用关键词 "SBRT "和 "CRPC "以及 "立体定向消融放疗 (SABR)" 和 "CRPC "进行了文献检索。该检索共检索到 108 篇文章,其中 19 篇被收录:结果:文献主要以回顾性系列研究为主。在一项随机II期试验中,对于患有远期寡进展的男性患者,使用雄激素受体通路抑制剂的SBRT可显著延长无进展生存期(PFS),包括无生化进展生存期(危险比为0.35,P 结论:SBRT可显著延长无进展生存期(PFS),包括无生化进展生存期(危险比为0.35,P 结论:SBRT可显著延长无进展生存期(PFS):在少转移性 CRPC 患者中,SBRT 可实现长期生化反应和 PFS。在少转移情况下,SBRT 可用于延长全身治疗的持续时间和疗效。尽管如此,目前的证据水平仍然很低,纳入前瞻性试验仍是这类患者的首选方案。
{"title":"The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.","authors":"Jennifer Le Guevelou, Francesco Cuccia, Ronan Flippot, Giuseppe Ferrera, Mario Terlizzi, Thomas Zilli, Renaud De Crevoisier, Jean-Michel Hannoun-Levi, Stephane Supiot, Paul Sargos, David Pasquier","doi":"10.1038/s41391-024-00862-8","DOIUrl":"10.1038/s41391-024-00862-8","url":null,"abstract":"<p><strong>Background: </strong>The onset of castration-resistance is associated with dismal outcomes in patients with prostate cancer (PCa). Metastasis directed therapy has been investigated in multiple disease settings and may improve outcomes in selected patients. Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC).</p><p><strong>Methods: </strong>The literature search was performed on March 2024, on Pubmed, using the keywords \"SBRT\" AND \"CRPC\", and \"stereotactic ablative radiotherapy (SABR)\" AND \"CRPC\". This search retrieved a total of 108 articles, 19 were included.</p><p><strong>Results: </strong>The literature is largely dominated by retrospective series. In men with metachronous oligoprogression, SBRT with androgen receptor pathway inhibitor significantly increased progression-free survival (PFS) including biochemical progression-free survival in a randomized phase II trial (hazard ratio of 0.35, p < 0.001). In patients continuing ADT, the bPFS ranged between 9.5 months to 17.9 months, and next systemic treatment-free survival (NEST-FS) reached up to 2 years. In men with induced oligoprogression, SBRT enabled NEST-FS up to 3 years. SBRT was well tolerated, with less than 5% grade 3 toxicity reported across studies.</p><p><strong>Conclusion: </strong>In the population of patients with oligometastatic CRPC, SBRT enables long-term biochemical response and PFS. In the oligoprogressive setting, SBRT could be integrated to prolong the duration and efficacy of systemic therapies. Nevertheless, the level of evidence remains very low and inclusion within prospective trials remain the preferred option for this population of patients.</p>","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141427452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Prostate Cancer and Prostatic Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1